Table 3.
Estimated total and excess cancer cases among people living with HIV in the United States in 2010, by demographic and HIV-related characteristics
| Characteristic | Estimated cases* | Percentage excess or deficit† (95% CI) | Percentage of total excess‡ (95% CI) | ||
|---|---|---|---|---|---|
| Total No. (95% CI) | Expected No. | Excess or deficit No. (95% CI) | |||
| Age, y | |||||
| 0–14 | 4 (2 to 8) | 1 | 4 (1 to 8) | 87 (70 to 93) | 0 (0 to 0) |
| 15–29 | 350 (300 to 400) | 30 | 320 (280 to 370) | 93 (92 to 94) | 8 (7 to 9) |
| 30–39 | 970 (890 to 1080) | 140 | 830 (750 to 930) | 85 (84 to 87) | 21 (19 to 23) |
| 40–49 | 2370 (2200 to 2560) | 760 | 1610 (1450 to 1810) | 68 (66 to 70) | 41 (38 to 44) |
| 50–59 | 2540 (2370 to 2740) | 1590 | 950 (780 to 1150) | 37 (33 to 42) | 24 (21 to 27) |
| 60–69 | 1240 (1120 to 1380) | 1020 | 220 (100 to 360) | 18 (9 to 26) | 6 (3 to 8) |
| ≥70 | 290 (250 to 350) | 310 | -20 (-60 to 40) | -6 (-21 to 11) | 0 (0 to 1) |
| Sex | |||||
| Male | 6240 (5880 to 6710) | 3020 | 3210 (2850 to 3690) | 52 (49 to 55) | 82 (78 to 86) |
| Female | 1530 (1370 to 1710) | 830 | 700 (540 to 890) | 46 (40 to 52) | 18 (14 to 22) |
| HIV risk group | |||||
| MSM§ | 4540 (4260 to 4920) | 2000 | 2540 (2260 to 2920) | 56 (53 to 59) | 65 (61 to 69) |
| Male heterosexual | 730 (640 to 830) | 410 | 320 (230 to 420) | 44 (36 to 51) | 8 (6 to 10) |
| Female heterosexual | 980 (860 to 1120) | 570 | 410 (290 to 550) | 42 (34 to 49) | 10 (8 to 13) |
| Male IDU | 920 (840 to 1030) | 590 | 320 (240 to 430) | 35 (29 to 42) | 8 (7 to 10) |
| Female IDU | 520 (450 to 590) | 240 | 270 (210 to 350) | 53 (46 to 59) | 7 (5 to 9) |
| Other/unknown | 80 (70 to 90) | 30 | 50 (40 to 60) | 59 (55 to 64) | 1 (1 to 1) |
| Time since an AIDS diagnosis | |||||
| HIV-only | 2810 (2620 to 3060) | 1430 | 1380 (1190 to 1630) | 49 (45 to 53) | 35 (32 to 38) |
| 1–3 months | 240 (210 to 280) | 20 | 220 (190 to 260) | 91 (90 to 92) | 6 (5 to 6) |
| 4–24 months | 540 (480 to 600) | 160 | 370 (320 to 440) | 70 (66 to 73) | 10 (8 to 11) |
| 25–60 months | 760 (690 to 840) | 320 | 440 (370 to 520) | 58 (53 to 62) | 11 (10 to 13) |
| >60 months | 3410 (3170 to 3720) | 1910 | 1500 (1260 to 1800) | 44 (40 to 48) | 38 (35 to 42) |
| Race/ethnicity | |||||
| Non-Hispanic white | 2870 (2670 to 3130) | 1490 | 1380 (1180 to 1640) | 48 (44 to 52) | 35 (32 to 38) |
| Non-Hispanic black | 3290 (3080 to 3560) | 1820 | 1470 (1260 to 1740) | 45 (41 to 49) | 38 (34 to 41) |
| Hispanic/Latino | 1270 (1170 to 1390) | 450 | 820 (720 to 940) | 64 (61 to 67) | 21 (19 to 23) |
| Other/unknown | 330 (270 to 410) | 90 | 240 (180 to 320) | 74 (67 to 79) | 6 (5 to 8) |
* Cancer cases are rounded to the nearest ten and may not always sum exactly. IDU = injection drug users; MSM = men who have sex with men.
† The percentage excess is calculated as excess/total; the percentage deficit is calculated as deficit/expected (see Methods).
‡ Deficit cancers are set equal to zero to calculate percent of total excess.
§ Individuals who are both MSM and IDU are classified as MSM.